Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 3 Solid Tumors 2 Hypoxia 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Melanoma 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Kidney Neoplasms 1 Gastrointestinal Stromal Tumors 1 Esophageal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 10 Docetaxel 8 senaparib 7 Injections 7 Capecitabine 7 Paclitaxel 6 Cisplatin 6 Irinotecan 5 Fluorouracil 5 Leucovorin 4 Cyclophosphamide 4 Bevacizumab 4 tislelizumab 3 pertuzumab 3 fludarabine 3 atezolizumab 3 Rifampin 3 Oxaliplatin 3 Itraconazole 3 Gemcitabine 3 ontuxizumab 2 navoximod 2 fluzoparib 2 durvalumab 2 Trastuzumab 2 Nivolumab 2 Midazolam 2 Hydroxychloroquine 2 Carboplatin 2 130-nm albumin-bound paclitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Solid Tumor × TH 302 × Clear all

NCT02076230 2016-06-10

A Phase 1 TH-302 Mass Balance Trial

Merck KGaA, Darmstadt, Germany

Phase 1 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡